Ryzneuta
NDC Package 73491-627-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Ryzneuta is a . Marketed by Evive Biotechnology Singapore Pte. Ltd., this product is identified by NDC 73491-627 and is authorized under FDA application BLA761134.

Identification & Billing

NDC Package Code
73491-627-01
Package Description
1 SYRINGE in 1 CARTON / 1 mL in 1 SYRINGE
Product Code
73491-627
11-Digit Billing Format
73491062701

Clinical Specifications

Proprietary Name
Ryzneuta
Dosage Form
-

Regulatory & Marketing

Labeler Name
Evive Biotechnology Singapore Pte. Ltd.
FDA Application #
BLA761134
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
11-23-2023
End Marketing Date
02-20-2025
Listing Expiration
02-20-2025
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 73491-627-01 identifies a specific commercial package of 1 syringe in 1 carton / 1 ml in 1 syringe of Ryzneuta, labeled by Evive Biotechnology Singapore Pte. Ltd.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Evive Biotechnology Singapore Pte. Ltd. on November 23, 2023. The current certification is valid through February 20, 2025.

How is this Evive Biotechnology Singapore Pte. Ltd. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 73491062701. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
73491-627-01
11-Digit CMS (5-4-2)
73491-0627-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.